Variation in Anticoagulation Practices in the Congenital Cardiac Catheterization Lab: Results of a Multinational PICES Survey
The complex nature of congenital heart disease (CHD) has hindered the establishment of management standards for peri-catheterization anticoagulation. We sought to describe anticoagulation practice variability among providers performing cardiac catheterization in children and adults with CHD. A web-based survey (http://www.surveymonkey.com) was distributed to pediatric and congenital interventional cardiologists. Respondents were queried on their training, practice setting, years in practice, and case volume. Clinical questions focused on general anticoagulation strategies and on five common clinical scenarios: two diagnostic (biventricular circulation, single ventricle physiology) and three interventional cardiac catheterizations (atrial septal defect closure, pulmonary artery stenting in Fontan circulation, stent placement for coarctation of aorta). Seventy-seven pediatric and congenital interventional cardiologists responded to the survey (81% in the United States). Twenty-six (36%) worked in a public medical institution; 57% worked in a free-standing children’s hospital. Twenty-six percent had been in practice for < 5 years and 32% for > 15 years; 75% completed additional training in interventional congenital cardiology. The median number of cases performed was 200/year (IQR 110); median number of interventional cases was 100/year (IQR 100). Responses to general queries and specific clinical scenarios suggested significant variation in anticoagulation practices, including monitoring of anticoagulation during catheterization, protamine use, and outpatient anticoagulation after catheterization. Practices not only varied between providers but also between different clinical scenarios. Practice patterns did not correlate with provider experience or case volume. Management of anticoagulation in the congenital cardiac catheterization lab varies from operator to operator. Our study may provide some initial insight and context for discussion regarding anticoagulation in a field of increasingly heterogeneous interventional techniques and patient substrates. Future studies would be helpful to better define “best practices” for peri-procedural thromboprophylaxis in patients with congenital heart disease.
KeywordsSurvey Cardiac catheterization Anticoagulation Quality improvement
NWT contributed to the concept and design of this study; data collection, analysis and interpretation; drafting and critical revision of the article; statistical analysis; and final approval of the manuscript. BHG, BMG, and GJM contributed to the concept and design of this study; data analysis and interpretation; critical revision of the article; and final approval of the manuscript.
Compliance with Ethical Standards
Conflict of interest
The authors have no financial or other conflicts of interest related to this study.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 3.Bergersen L, Marshall A, Gauvreau K et al (2010) Adverse event rates in congenital cardiac catheterization—a multi-center experience. Catheter Cardiovasc Interv 75:389–400Google Scholar
- 10.AGA/St. Jude Medical I. AMPLATZER(TM) Septal Occluder and Delivery System: Instructions for Use, 2016Google Scholar
- 12.Shapira N, Schaff HV, Piehler JM, White RD, Still JC, Pluth JR (1982) Cardiovascular effects of protamine sulfate in man. J Thorac Cardiovasc Surg 84:505–514Google Scholar